Patents Represented by Attorney, Agent or Law Firm Diane L. Marschang
-
Patent number: 6294348Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.Type: GrantFiled: February 9, 1998Date of Patent: September 25, 2001Assignees: Genentech Inc., Tularik, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 6177543Abstract: Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10×107 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.Type: GrantFiled: March 19, 1998Date of Patent: January 23, 2001Assignee: Genentech, Inc.Inventors: Bharat B. Aggarwal, Patrick W. Gray, Glenn E. Nedwin
-
Patent number: 6063585Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.Type: GrantFiled: February 9, 1998Date of Patent: May 16, 2000Assignees: Genetech, Inc., Tularik, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 6060303Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.Type: GrantFiled: February 9, 1998Date of Patent: May 9, 2000Assignees: Genetech, Inc., Tularik, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 6046048Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.Type: GrantFiled: January 8, 1997Date of Patent: April 4, 2000Assignee: Genetech, Inc.Inventors: Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
-
Patent number: 6030945Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.Type: GrantFiled: January 9, 1996Date of Patent: February 29, 2000Assignee: Genentech, Inc.Inventor: Avi J. Ashkenazi
-
Patent number: 6004553Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.Type: GrantFiled: February 9, 1998Date of Patent: December 21, 1999Assignees: Genentech, Inc., Tularik, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 5889155Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 31, 1995Date of Patent: March 30, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5879910Abstract: The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.Type: GrantFiled: February 9, 1994Date of Patent: March 9, 1999Assignee: Genetech, Inc.Inventors: Paul J. Godowski, Natalie A. Lokker, Melanie R. Mark
-
Patent number: 5855918Abstract: The invention provides methods for treating cystic fibrosis and other pathological conditions in mammals using hepatocyte growth factor ("HGF"). The invention also provides articles of manufacture and kits containing HGF.Type: GrantFiled: September 12, 1996Date of Patent: January 5, 1999Assignees: Genentech, Inc., Children's Hospital Medical Center of Northern California, Regents of the University of CAInventors: Randall J. Mrsny, Ben-Quan Shen, Jonathan H. Widdicombe
-
Patent number: 5851984Abstract: Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation or differentiation of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.Type: GrantFiled: August 16, 1996Date of Patent: December 22, 1998Assignee: Genentech, Inc.Inventors: William Matthews, Timothy W. Austin
-
Patent number: 5834250Abstract: The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptides are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide.Type: GrantFiled: June 30, 1997Date of Patent: November 10, 1998Assignee: Genentech, Inc.Inventors: James A. Wells, Brian C. Cunningham
-
Patent number: 5824509Abstract: Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10.times.10.sup.7 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.Type: GrantFiled: May 19, 1995Date of Patent: October 20, 1998Assignee: Genentech, Inc.Inventors: Bharat B. Aggarwal, Patrick W. Gray, Glenn E. Nedwin
-
Patent number: 5795967Abstract: Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis factor. The antagonists are useful in suppressing transplantation immunity and in the treatment of autoimmune diseases.Type: GrantFiled: June 7, 1995Date of Patent: August 18, 1998Assignee: Genentech, Inc.Inventors: Bharat B. Aggarwal, Michael A. Palladino, Mohamed R. Shalaby
-
Patent number: 5770704Abstract: The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their respective receptors inducing receptor oligomerization.Type: GrantFiled: January 31, 1997Date of Patent: June 23, 1998Assignee: Genentech, Inc.Inventor: Paul J. Godowski
-
Patent number: 5763394Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: GrantFiled: September 14, 1993Date of Patent: June 9, 1998Assignee: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Patent number: 5763584Abstract: The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their respective receptors inducing receptor oligomerization.Type: GrantFiled: May 5, 1995Date of Patent: June 9, 1998Assignee: Genentech, Inc.Inventor: Paul J. Godowski
-
Patent number: 5747023Abstract: Methods and compositions are provided which include use of lymphotoxin (LT) and one or more other anti-cancer therapies for treating cancer in vivo or ex vivo. LT can be employed, for instance, with chemotherapy or radiation therapy to provide improved anti-cancer therapy.Type: GrantFiled: April 7, 1995Date of Patent: May 5, 1998Assignee: Genentech, Inc.Inventors: David V. Goeddel, Grace H. W. Wong
-
Patent number: 5696086Abstract: The invention provides methods for stimulating megakaryocyte maturation and thrombocyte production using macrophage stimulating protein ("MSP"). In the methods, an effective amount of MSP can be administered in vivo, or alternatively, be used to stimulate maturation of megakaryocytes and produce thrombocytes in vitro. Methods for treating thrombocytopenia in a mammal with MSP are also provided. Kits and articles of manufacture which include MSP are further provided.Type: GrantFiled: November 3, 1994Date of Patent: December 9, 1997Assignees: Genentech, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Hava Karsenty Avraham, Paul J. Godowski
-
Patent number: 5686292Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: GrantFiled: June 2, 1995Date of Patent: November 11, 1997Assignee: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly Helen Tabor